Compounds > 6-phosphonylmethoxyethoxy-2-4-diaminopyrimidine

6-phosphonylmethoxyethoxy-2-4-diaminopyrimidine and Hepatitis-B--Chronic

6-phosphonylmethoxyethoxy-2-4-diaminopyrimidine has been researched along with Hepatitis-B--Chronic* in 1 studies

Other Studies

1 other study(ies) available for 6-phosphonylmethoxyethoxy-2-4-diaminopyrimidine and Hepatitis-B--Chronic

ArticleYear
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6

    The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.

    Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidine Nucleosides; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication

2007